Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

NCT07480863 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma(MZL)

Interventions

DRUG: Orelabrutinib
DRUG: Zuberitamab
DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Prednisoneacetatetablets

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]